pharma · Thyroid eye disease · Thyroid Eye Disease · VRDN
Viridian Pharma
Viridian Pharma Ltd
NovaPharmaNews editorial coverage mentioning Viridian Pharma — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 200 Market Street, ELMWOOD PARK, NJ 07407, US
- Founded
- 2017
- Employees
- 2
- Programs
- 13
- Drugs
- 11
- Patents
- 3
News & analysis
NovaPharmaNews articles mentioning Viridian Pharma — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Viridian Pharma — regulatory, clinical, and market analysis.
Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM
Vir Biotechnology is undergoing significant leadership changes post-AGM, with a board reshuffle and key governance votes set to influence its strategic direction. Investors and pharmaceutical BD teams should monitor these developments for potential shifts in clinical trial focus and market positioning.
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
Gilead Sciences has achieved a significant milestone with the FDA approval of bulevirtide, the first drug to treat chronic hepatitis D. This landmark decision intensifies the competitive landscape as Bay Area rivals Vir Biotechnology and Mirum Pharmaceuticals advance their own therapies.